A Phase 1 Dose Escalation Study of IGM-2323, a Novel Anti-CD20 x Anti-CD3 IgM T Cell Engager (TCE) in Patients with Advanced B-Cell Malignancies

63rd American Society of Hematology (ASH) Annual Meeting and Exposition, December 11-14, 2021 Session: 623. Mantle Cell, Follicular, and Other B-Cell Lymphomas: Clinical and Epidemiological: ...

SITC Abstract: IGM-7354 is an anti-PD-L1 IgM antibody and IL-15 cytokine fusion that enhances NK and CD8+ T cell proliferation and tumor cytotoxicity plus potently reverses T cell exhaustion

SITC 2021 –  The Society for Immunotherapy of Cancer 36th Annual Meeting & Pre-Conference Programs    November 12-14, 2021 Thierry D. Giffon; Melanie Desbois; Dean ...

Multimeric IgM Antibodies Targeting DR5 are Potent and Rapid Inducers of Tumor Cell Apoptosis In Vitro and In Vivo

PEGS Europe, Barcelona, Spain – November 4, 2021 Angus M. Sinclair, PhD, Vice President, Immuno-oncology Research IGM Biosciences, Inc., 325 E Middlefield Road, Mountain View, ...

Abstract #132: A Phase 1 Dose Escalation Study of IGM-2323, a Novel Anti-CD20 x Anti-CD3 IgM T Cell Engager (TCE) in Patients with Advanced B-Cell Malignancies

The 63rd ASH Annual Meeting and Exposition – December 11-14, 2021

Multimeric IgM Antibodies Targeting DR5 are Potent and Rapid Inducers of Tumor Cell Apoptosis In Vitro and In Vivo

PEGS Europe, Barcelona, Spain – November 4, 2021 Angus M. Sinclair, PhD, Vice President, Immuno-oncology Research IGM Biosciences, Inc., 325 E Middlefield Road, Mountain View, ...

Mechanistic evaluation of anti-DR5 IgM antibody IGM-8444 with potent tumor cytotoxicity, without in vitro hepatotoxicity

AACR Annual Meeting 2021 Virtual – April 10-15, 2021 Session: Therapeutic Mechanisms of Novel Anticancer Agent, Abstract No. 52

Abstract: Mechanistic evaluation of anti-DR5 IgM antibody IGM-8444 with potent tumor cytotoxicity, without in vitro hepatotoxicity

AACR Annual Meeting – April 10-15, 2021 Regular abstract titles, authors, and text released – March 10, 2021